Monon Bioventures receives SBIR grant to develop glioblastoma therapeutic created at Purdue

By | September 23, 2022
Monon Bioventures LLC has received a one-year, $398,314 Phase I Small Business Innovation Research, or SBIR grant from the National Cancer Institute to demonstrate the feasibility of manufacturing a glioblastoma therapeutic created at the Purdue University College of Pharmacy.